Monte Rosa Therapeutics, Inc. (GLUE) stock
GLUENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/3012% above fair value
$9.16−0.21 (-2.24%)
Close on Nov 16, 2026Market cap $781.47MP/E –Yield –
Monte Rosa Therapeutics profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Monte Rosa Therapeutics's profit margin for the twelve months ending Sep 30, 2026 was -186.2%. For fiscal 2025 it was -31.2%, against -96.1% the year before.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -31.2% | +64.9 |
| FY2024 | Dec 31, 2024 | -96.1% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | 5.6% | +217.7 |
| Q2 FY2026 | Jun 30, 2026 | -483.9% | −430.9 |
| Q1 FY2026 | Mar 31, 2026 | -1057.1% | −1112.3 |
| Q4 FY2025 | Dec 31, 2025 | -1658.0% | −1680.2 |
| Q3 FY2025 | Sep 30, 2025 | -212.1% | +46.8 |
| Q2 FY2025 | Jun 30, 2025 | -53.0% | +592.6 |
| Q1 FY2025 | Mar 31, 2025 | 55.2% | +3059.7 |
| Q4 FY2024 | Dec 31, 2024 | 22.2% | – |
| Q3 FY2024 | Sep 30, 2024 | -258.9% | – |
| Q2 FY2024 | Jun 30, 2024 | -645.6% | – |
| Q1 FY2024 | Mar 31, 2024 | -3004.5% | – |
See a number that looks wrong?